TMB-001

Phase 3Small molecule

TTimber Pharmaceuticals Inc.

TMB-001 is one of 9 small molecule programs targeting Ichthyosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

IchthyosisActive, not recruiting

IchthyosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Ichthyosis

#DrugCompanyPhaseTrials

Cosentyx

Novartis

Approved

1 2

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Approved

1 3

Accutane

CConrado Roberto Hoffmann Filho

Phase 2

1 4

Garamycin

SSchering-Plough

Phase 2

1 5

Stelara

Johnson & Johnson

Phase 1

1 6

Imsidolimab

VVanda Pharmaceuticals

Phase 2

1 7

TMB-001

TTimber Pharmaceuticals Inc.

Phase 3

1 8

Monolaurin

CCellegy Pharmaceuticals

Phase 3

1 9

CD5789 (trifarotene)

MMayne Pharma International Pty Ltd

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ichthyosis1 trial

The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis

Completed·TTimber Pharmaceuticals Inc.·Phase 3·NCT05295732·153 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TMB-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TMB-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TMB-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Timber Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTimber Pharmaceuticals Inc.

TMB-001

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ichthyosis1 trial

References

Drug Info

Quick Facts

Related News